The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 11000 participants.
Also called NCT03129490
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 11,000 participants
- Sponsor
- Registry
-
NCT03129490
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03129490. Randomized; single masking; primary purpose prevention. Start 2023-04-01 (actual); primary completion 2027-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
- Acronym
- DANNOAC-AF
- Condition
- Atrial Fibrillation
- Condition
- Atrial Flutter
- Intervention (Drug)
- Dabigatran Etexilate Oral Capsule
- Intervention (Drug)
- Rivaroxaban Oral Tablet
- Intervention (Drug)
- Edoxaban Oral Tablet
- Intervention (Drug)
- Apixaban Oral Tablet
- Lead sponsor
- Herlev and Gentofte Hospital
Record details
- Record id
cardio:ct-nct03129490- Content hash
6cf242b8a6d493476597e91eeb32eaa14231f9254b2251adcff9df3a030bc3df